Core Viewpoint - Junshi Biosciences (01877) expects to achieve approximately CNY 2.5 billion in revenue for the fiscal year 2025, representing a year-on-year growth of about 28.32% [1] Financial Performance - The projected R&D expenses for 2025 are approximately CNY 1.353 billion, reflecting a year-on-year increase of about 6.10% [1] - The expected net loss attributable to the parent company for 2025 is around CNY 873 million, which is a reduction of approximately 31.85% compared to the previous year [1] - After excluding the impact of share-based payments, the net loss is projected to be about CNY 799 million, a decrease of approximately 37.62% year-on-year [1] - The net loss attributable to the parent company, excluding non-recurring gains and losses, is expected to be around CNY 985 million, down by about 23.64% year-on-year [1] - After excluding the impact of share-based payments and non-recurring gains and losses, the net loss is projected to be approximately CNY 911 million, a reduction of about 29.37% year-on-year [1] Product and Market Development - The increase in revenue is primarily due to the growth in sales of commercialized drugs, particularly the core product Toripalimab injection (brand name: Tuoyi), which saw significant sales growth in the domestic market [1] - As of the date of this announcement, Tuoyi has been approved for 12 indications in mainland China and is the only anti-PD-1 monoclonal antibody included in the national medical insurance catalog for the treatment of renal cancer, triple-negative breast cancer, and melanoma [1] - The company continues to expand its global commercialization network, with Toripalimab approved in over 40 countries and regions, including mainland China, Hong Kong, the United States, the European Union, and others [2] Strategic Initiatives - Despite the expected net loss for 2025, the company has significantly narrowed its loss compared to the previous year, attributed to the implementation of the "quality improvement and efficiency enhancement" action plan [2] - The company has improved its commercialization capabilities while strengthening cost control and resource focus [2] - The company is advancing multiple innovative drugs with international market competitiveness, including JS207 (a PD-1/VEGF dual antibody), JS212 (an EGFR/HER3 ADC), and JS213 (a PD-1/IL-2 fusion protein), which are in various stages of clinical trials [2] - JS207 is currently in Phase II clinical research, exploring combinations with chemotherapy, monoclonal antibodies, and ADCs across multiple tumor types [2] - The company aims to accelerate pipeline development and push more advantageous products and indications into the registration clinical trial phase [2]